In this episode FirstWord Pharma PLUS executive editors Simon King and Michael Flanagan discuss new data for Gilead Sciences’ remdesivir showing that it accelerated the recovery time of hospitalised patients with advanced COVID-19 by 31%. They also analyse the race to develop an effective vaccine and breakdown the impact of the pandemic on pharma’s sales and operating performance.
Thanks for listening and please do forward any feedback and suggestions to firstname.lastname@example.org
The FirstWord team
To read more Spotlight On articles, click here.